BioMarin Pharmaceuticals BMRN Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's unrealized gains on investments?
- BioMarin Pharmaceuticals (BMRN) reported unrealized gains on investments of $0 in Q1 2026.
- How has BioMarin Pharmaceuticals's unrealized gains on investments changed year-over-year?
- BioMarin Pharmaceuticals's unrealized gains on investments decreased by 100.0% year-over-year, from $4.05M to $0.
- What is the long-term trend for BioMarin Pharmaceuticals's unrealized gains on investments?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's unrealized gains on investments has grown at a -0.7% compound annual growth rate (CAGR), from $5.07M to $4.9M.